Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
AssigneeModeX Therapeutics, Inc.
InventorsRonnie Rong WEI, Ling XU, Zhi-Yong YANG, Edward SEUNG, Gary J. NABEL
Life of this patent
Estimating the term…
Abstract
Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; chimeric antigen receptors (CARs); immune cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.
Claims21
1-74. (canceled)
An antigen binding polypeptide complex comprising a first polypeptide and a second polypeptide,
- wherein the first polypeptide has a structure represented by:
- VL1-L1-VL2-L2-VL3-L3-VH3-L4-VH2-L5-VH1-Fc;
- VH1-L1-VH2-L2-VH3-L3-VL3-L4-VL2-L5-VL1-Fc;
- VL1-L1-VH2-L2-VL3-L3-VH3-L4-VL2-L5-VH1-Fc;
- VH1-L1-VL2-L2-VH3-L3-VL3-L4-VH2-L5-VL1-Fc;
- VL1-L1-VL2-L2-VH3-L3-VL3-L4-VH2-L5-VH1-Fc;
- VH1-L1-VH2-L2-VL3-L3-VH3-L4-VL2-L5-VL1-Fc;
- VL1-L1-VH2-L2-VH3-L3-VL3-L4-VL2-L5-VH1-Fc;
- VH1-L1-VL2-L2-VL3-L3-VH3-L4-VH2-L5-VL1-Fc;
- VL1-L1-VL2-L2-VL3-L3-VH3-L4-VH2-L5-VH1-L6-Fc;
- VH1-L1-VH2-L2-VH3-L3-VL3-L4-VL2-L5-VL1-L6-Fc;
- VL1-L1-VH2-L2-VL3-L3-VH3-L4-VL2-L5-VH1-L6-Fc;
- VH1-L1-VL2-L2-VH3-L3-VL3-L4-VH2-L5-VL1-L6-Fc;
- VL1-L1-VL2-L2-VH3-L3-VL3-L4-VH2-L5-VH1-L6-Fc;
- VH1-L1-VH2-L2-VL3-L3-VH3-L4-VL2-L5-VL1-L6-Fc;
- VL1-L1-VH2-L2-VH3-L3-VL3-L4-VL2-L5-VH1-L6-Fc;
- or
- VH1-L1-VL2-L2-VL3-L3-VH3-L4-VH2-L5-VL1-L6-Fc;
- wherein the second polypeptide has a structure represented by:
- VL4-L7-VH4-Fc;
- VH4-L7-VL4-Fc;
- VL4-L7-VH4-L8-Fc;
- VH4-L7-VL4-L8-Fc;
- VL4-L7-VL5-L8-VH5-L9-VH4-Fc;
- VH4-L7-VH5-L8-VL5-L9-VL4-Fc;
- VL4-L7-VL5-L8-VH5-L9-VH4-L10-Fc;
- VH4-L7-VH5-L8-VL5-L9-VL4-L10-Fc;
- VL4-L7-VL5-L8-VL6-L9-VH6-L10-VH5-L11-VH4-Fc;
- VH4-L7-VH5-L8-VH6-L9-VL6-L10-VL5-L11-VL4-Fc;
- VL4-L7-VH5-L8-VL6-L9-VH6-L10-VL5-L11-VH4-Fc;
- VH4-L7-VL5-L8-VH6-L9-VL6-L10-VH5-L11-VL4-Fc;
- VL4-L7-VL5-L8-VH6-L9-VL6-L10-VH5-L11-VH4-Fc;
- VH4-L7-VH5-L8-VL6-L9-VH6-L10-VL5-L11-VL4-Fc;
- VL4-L7-VH5-L8-VH6-L9-VL6-L10-VL5-L11-VH4-Fc;
- VH4-L7-VL5-L8-VL6-L9-VH6-L10-VH5-L11-VL4-Fc;
- VL4-L7-VL5-L8-VL6-L9-VH6-L10-VH5-L11-VH4-L12-Fc;
- VH4-L7-VH5-L8-VH6-L9-VL6-L10-VL5-L11-VL4-L12-Fc;
- VL4-L7-VH5-L8-VL6-L9-VH6-L10-VL5-L11-VH4-L12-Fc;
- VH4-L7-VL5-L8-VH6-L9-VL6-L10-VH5-L11-VL4-L12-Fc;
- VL4-L7-VL5-L8-VH6-L9-VL6-L10-VH5-L11-VH4-L12-Fc;
- VH4-L7-VH5-L8-VL6-L9-VH6-L10-VL5-L11-VL4-L12-Fc;
- VL4-L7-VH5-L8-VH6-L9-VL6-L10-VL5-L11-VH4-L12-Fc;
- or
- VH4-L7-VL5-L8-VL6-L9-VH6-L10-VH5-L11-VL4-L12-Fc;
- and
- wherein:
- VL1 is a first immunoglobulin light chain variable region;
- VL2 is a second immunoglobulin light chain variable region;
- VL3 is a third immunoglobulin light chain variable region;
- VL4 is a fourth immunoglobulin light chain variable region;
- VL5 is a fifth immunoglobulin light chain variable region;
- VL6 is a sixth immunoglobulin light chain variable region;
- VH1 is a first immunoglobulin heavy chain variable region;
- VH2 is a second immunoglobulin heavy chain variable region;
- VH3 is a third immunoglobulin heavy chain variable region;
- VH4 is a fourth immunoglobulin heavy chain variable region;
- VH5 is a fifth immunoglobulin heavy chain variable region;
- VH6 is a sixth immunoglobulin heavy chain variable region;
- Fc is a region comprising an immunoglobulin heavy chain constant region 2 (CH2), an immunoglobulin heavy chain constant region 3 (CH3), and optionally, an immunoglobulin hinge;
- and
- L1-L12 are amino acid linkers.
Dependencies are inferred from the claim text.